Charles Schwab’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30.3M | Buy |
833,418
+51,437
| +7% | +$2.3M | ﹤0.01% | 1493 |
|
|
2025
Q4 | $36.4M | Buy |
781,981
+3,329
| +0.4% | +$148K | 0.01% | 1364 |
|
|
2025
Q3 | $32.4M | Buy |
778,652
+12,424
| +2% | +$397K | 0.01% | 1433 |
|
|
2025
Q2 | $22M | Buy |
766,228
+12,701
| +2% | +$392K | ﹤0.01% | 1618 |
|
|
2025
Q1 | $25.3M | Sell |
753,527
-5,599
| -0.7% | -$209K | ﹤0.01% | 1499 |
|
|
2024
Q4 | $38.8M | Buy |
759,126
+103,708
| +16% | +$5.8M | 0.01% | 1309 |
|
|
2024
Q3 | $33.5M | Buy |
655,418
+58,369
| +10% | +$3.01M | 0.01% | 1376 |
|
|
2024
Q2 | $26.7M | Buy |
597,049
+118,517
| +25% | +$5.47M | 0.01% | 1493 |
|
|
2024
Q1 | $22.4M | Buy |
478,532
+8,159
| +2% | +$319K | 0.01% | 1543 |
|
|
2023
Q4 | $16.7M | Buy |
470,373
+9,070
| +2% | +$278K | ﹤0.01% | 1696 |
|
|
2023
Q3 | $13.7M | Buy |
461,303
+110,565
| +32% | +$2.28M | ﹤0.01% | 1737 |
|
|
2023
Q2 | $6.32M | Buy |
350,738
+5,171
| +1% | +$103K | ﹤0.01% | 2133 |
|
|
2023
Q1 | $5.55M | Buy |
345,567
+2,512
| +0.7% | +$46.5K | ﹤0.01% | 2160 |
|
|
2022
Q4 | $6.28M | Buy |
343,055
+6,865
| +2% | +$121K | ﹤0.01% | 2096 |
|
|
2022
Q3 | $6.6M | Buy |
336,190
+4,519
| +1% | +$92.2K | ﹤0.01% | 2069 |
|
|
2022
Q2 | $6.19M | Buy |
331,671
+33,546
| +11% | +$669K | ﹤0.01% | 2099 |
|
|
2022
Q1 | $6.54M | Buy |
298,125
+8,390
| +3% | +$170K | ﹤0.01% | 2158 |
|
|
2021
Q4 | $8.23M | Buy |
289,735
+66,488
| +30% | +$1.64M | ﹤0.01% | 2101 |
|
|
2021
Q3 | $4.7M | Buy |
223,247
+27,326
| +14% | +$572K | ﹤0.01% | 2406 |
|
|
2021
Q2 | $3.69M | Buy |
195,921
+45,169
| +30% | +$794K | ﹤0.01% | 2494 |
|
|
2021
Q1 | $2.3M | Buy |
150,752
+29
| +0% | +$449 | ﹤0.01% | 2621 |
|
|
2020
Q4 | $2.13M | Buy |
150,723
+3,852
| +3% | +$53.7K | ﹤0.01% | 2579 |
|
|
2020
Q3 | $2.3M | Buy |
146,871
+11,897
| +9% | +$182K | ﹤0.01% | 2448 |
|
|
2020
Q2 | $2.37M | Buy |
134,974
+82,252
| +156% | +$1.4M | ﹤0.01% | 2364 |
|
|
2020
Q1 | $776K | Sell |
52,722
-225
| -0.4% | -$4.61K | ﹤0.01% | 2553 |
|
|
2019
Q4 | $1.33M | Buy |
52,947
+1,944
| +4% | +$37K | ﹤0.01% | 2521 |
|
|
2019
Q3 | $768K | Buy |
51,003
+4,857
| +11% | +$94.4K | ﹤0.01% | 2643 |
|
|
2019
Q2 | $1.15M | Buy |
46,146
+5,929
| +15% | +$147K | ﹤0.01% | 2529 |
|
|
2019
Q1 | $916K | Buy |
40,217
+6,343
| +19% | +$156K | ﹤0.01% | 2576 |
|
|
2018
Q4 | $1.02M | Sell |
33,874
-2,192
| -6% | -$61.7K | ﹤0.01% | 2535 |
|
|
2018
Q3 | $1.03M | Buy |
+36,066
| New | +$1.07M | ﹤0.01% | 2616 |
|
Other funds holding CRNX
FCM
DCM
VCM
VPM
EC